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Introduction: Cortisol effects on the brain are exerted through two distinct receptors,
inducing complex and even opposite effects on the cerebral structures implicated in the
various cognitive functions. High cortisol may also have deleterious effects on the brain
structures and contribute to neurodegeneration, in particular Alzheimer’s disease (AD),
via different mechanisms.
Objective: To examine the interrelationships between cortisol, cognitive impairment
and AD.
Methods: Review of the literature.
Results: Clinical studies found that elevated cortisol was associated with poorer overall
cognitive functioning, as well as with poorer episodic memory, executive functioning,
language, spatial memory, processing speed, and social cognition; while in animals,
glucocorticoid administration resulted in cognitive impairment and abnormal behavior.
In cognitively healthy subjects, higher cortisol levels have been associated with an
increased risk of cognitive decline and AD. Subjects with dementia and Mild Cognitive
Impairment (MCI) due to AD have been found to have higher CSF cortisol levels than
cognitively healthy controls. Elevated CSF cortisol may also be associated with a more
rapid cognitive decline in MCI due to AD. Elevated cortisol levels have been also
found in delirium. High cortisol may mediate the impact of stressful life events, high
neuroticism, depression, sleep disturbances, as well as cardiovascular risk factors on
cognitive performance, neurodegeneration, and cognitive decline. High cortisol may also
exert neurotoxic effects on the hippocampus, and promote oxidative stress and amyloid
β peptide toxicity. Further possible underlying mechanisms include the interactions of
cortisol with inflammatory mediators, neurotransmitters, and growth factors.
Conclusion: Elevated cortisol levels may exert detrimental effects on cognition and
contribute to AD pathology. Further studies are needed to investigate cortisol-reducing
and glucocorticoidreceptor modulating interventions to prevent cognitive decline.
Keywords: cognition, cortisol, memory, executive functions, dementia
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INTRODUCTION
Corticosteroids seem to be among the hormones with the most
important effects on the brain function. Indeed, corticosteroids
have been associated with effects on mood, stress, anxiety, sleep,
appetite, as well as cognition (Lupien et al., 2007; Wolkowitz et al.,
2009; Copinschi and Caufriez, 2013).
Once released from the adrenal cortex, cortisol, the main
glucocorticoid in humans, easily crosses the blood–brain barrier,
owing to its lipophilic character (Wolkowitz et al., 2009). Cortisol
binds to specific intracellular receptors in the brain, in particular
in regions implicated in cognitive functions (McEwen, 2007;
Daskalakis et al., 2013; Vogel et al., 2016). Once activated, these
receptors bind to “ hormone response elements” in the DNA and
regulate the transcription of target genes (Joels, 2006).
The resulting effects on cognition seem to be complex and
involve several cognitive domains (Lupien et al., 2007; Lee C.M.
et al., 2008; Tatomir et al., 2014; Geerlings et al., 2015; Vogel et al.,
2016). Different levels of cortisol likely produce different and
even sometimes opposite effects (de Kloet et al., 1999; Joels, 2006).
While some of these effects are acute (Lupien and McEwen, 1997;
Lupien et al., 2002; Meir Drexler and Wolf, 2016), some appear
to be long-lasting and may even involve long-term changes in the
brain structure (Geerlings et al., 2015).
Altered Hypothalamic-Pituitary-Adrenal (HPA) axis
functioning, and in particular high cortisol levels in the
elderly have been associated with an increased risk for dementia
and Alzheimer’s disease (AD) (Lupien et al., 1999; Rothman and
Mattson, 2010; Ennis et al., 2017; Notarianni, 2017).
A better understanding of these interrelationships between
cortisol, cognition and dementia may open the door to new
prevention and therapeutic options involving the HPA axis. The
effects of cortisol on emotional memory had already led to
therapeutic trials of corticosteroids and corticosteroid receptor
antagonists/modulators in AD (Pineau et al., 2016), as well as
in treating or preventing post-traumatic stress disorder (PTSD)
(Daskalakis et al., 2013), as well as in treating depression
(Wolkowitz and Reus, 1999; Kling et al., 2009).
GLUCOCORTICOID RECEPTORS AND
CORTISOL EFFECTS ON COGNITION
Cortisol exerts its effects on cognition through two types of
receptors: type I (Mineralocorticoid Receptors, MRs) and type
II (Glucocorticoid Receptors, GRs) (Joels, 2006; Daskalakis et al.,
2013). Surprisingly, the MRs display 6 to 10 times higher affinity
for glucocorticoids, mainly cortisol, than GRs (de Kloet et al.,
1999; Joels, 2006).
These receptors are expressed differently throughout the
brain. Indeed, the hippocampus, mainly implicated in episodic
memory, expresses both MRs and GRs, whilst the prefrontal
cortex, primarily responsible for executive functions, only
expresses GRs (Lupien et al., 2007; McEwen, 2007). While
MRs have been associated with positive/enhancing effects on
the cognitive performance, GRs have, on the contrary, been
linked to negative inhibitory effects. In this regard, it has
been found that infusion of a GR antagonist, but not of MR
antagonist, in the medial prefrontal cortex of a mouse blocked
the deleterious effects of glucocorticoids on working memory
(Barsegyan et al., 2010).
Cortisol effects on the hippocampus-related cognitive
performance have often been described by the means of an
inverted-U shape plot (Figure 1). Indeed, in the hippocampus,
where both GRs and MRs are expressed, moderate levels of
cortisol only activate the receptors with the higher affinity,
i.e., MRs, leading to memory enhancement effects. As cortisol
levels increase, this positive effect increases till MRs are
saturated. Starting from this point, as cortisol levels rise, GRs are
increasingly activated thus leading to increasingly detrimental
effects on the memory. Distinctly, the effects of cortisol on
executive functions are likely more linear. Since the prefrontal
cortex region, mostly responsible for executive functions, only
expresses GRs, higher levels of cortisol may lead to worsened
executive functioning (Figure 2; Lupien et al., 2007; McEwen,
2007). The fact that both adrenal insufficiency and Cushing’s
disease have been associated with impaired declarative memory
(Forget et al., 2016; Tiemensma et al., 2016) bolsters this biphasic
effect hypothesis. Another argument is that the administration
of the MR agonist fludrocortisone has been found to improve
verbal and visuospatial memory performance in young as well as
elderly healthy subjects (Hinkelmann et al., 2015); whereas the
administration of hydrocortisone (mimicking the endogenous
cortisol effects on both GRs and MRs) has been shown to
enhance at lower doses yet impair at higher doses verbal memory
retrieval in healthy subjects (Domes et al., 2005).
These effects that cortisol exerts on the brain structures
involved in cognition are possibly mediated by modifications
in responses to serotonin, in β-adrenergic receptor activation,
in calcium influx, as well as in long-term potentiation
(LTP), a process referring to a long-term strengthening of
synaptic connections contributing to memory formation and
consolidation (Joels, 2006; Lupien et al., 2007). Indeed, GR
activation facilitates β-adrenergic signaling thus leading to the
formation of adenosine 3′,5′-cyclic monophosphate (cAMP)
and cAMP-dependent protein kinase (PKA). This pathway,
once activated, is thought to inhibit the medial prefrontal
cortex thus leading to an impairment in frontal functions,
in particular working memory (McGaugh and Roozendaal,
2002; Barsegyan et al., 2010). Glucocorticoids have also been
found to display certain effects on the hippocampus via actions
on the serotoninergic system following the same biphasic
pattern as described in Figure 1. Indeed, glucocorticoids can
promote via MRs and, at the same time, inhibit via GRs
the 5HT1A activation in hippocampal CA1 pyramidal cells
(de Kloet et al., 2018).
Moreover, glucocorticoids have been reported to alter LTP
in opposite directions depending on the MR/GR activation
ratio: when the MR/GR activation ratio is high (central part of
the inverted U-shaped plot, Figure 1), LTP is enhanced thus
improving long-term memory consolidation. On the contrary,
when the MR/GR ratio is low (extremes of the inverted U-shaped
plot, Figure 1), LTP is suppressed thus worsening long-term
memory consolidation (de Kloet et al., 1999; Lupien et al., 2007).
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FIGURE 1 | Dose–response relationship between the memory performance and the cortisol levels. The first part of the plot shows that memory performance
increases as cortisol levels increase (due to the activation of mineralocorticoid receptors or MRs). As soon as the MRs are saturated, further increase in cortisol levels
activates the glucocorticoids receptors or GRs and memory performance decreases. Adapted with permission from Lupien et al. (2007).
FIGURE 2 | Hypothetical dose–response relationship between the executive
functions performance and the cortisol levels. As the prefrontal cortex only
expresses GRs, the higher the cortisol levels, the poorer the executive
functions performance.
In clinical studies, most studies examining the link between
cortisol levels and global cognitive performance among non-
demented older adults found that higher cortisol levels have been
associated with poorer overall cognitive performance (Lupien
et al., 2007; Lee B.K. et al., 2008; Ouanes et al., 2017a; Sang
et al., 2018). Likewise, most (Beluche et al., 2010; Geerlings
et al., 2015; Segerstrom et al., 2016; Ouanes et al., 2017a,b;
Echouffo-Tcheugui et al., 2018), even though not all (Lee B.K.
et al., 2008) studies exploring the relationship between episodic
memory and cortisol levels have found an association between
elevated cortisol and poorer episodic memory among older adults
without dementia. These findings suggest that, even at levels that
are within the normal range, cortisol can still activate GRs, and
not just MRs. This also suggests that relatively small differences
in cortisol levels can exhibit significant effects on memory
performance. Studies exploring the relationship between cortisol
levels and prefrontal cortex-mediated cognitive functions, mainly
executive functions, processing speed and working memory,
have found more discrepant results: while the expected negative
association was reported in certain studies (Lee B.K. et al.,
2008; Beluche et al., 2010; Geerlings et al., 2015), other studies
failed to find such an association (Ouanes et al., 2017a,b;
Echouffo-Tcheugui et al., 2018).
The differences in populations, assessment tools, as well as
the likely effects of possible confounding factors including age,
gender, educational level, as well as other neuroendocrine and
psychological factors might explain these discrepancies.
CORTISOL AND CEREBRAL
STRUCTURAL CHANGES
High cortisol has also been linked to decreased volume of
several brain regions involved in cognitive functions. In fact, in
a study by Geerlings et al. (2015) involving 4244 non-demented
subjects, elevated evening cortisol was found to be associated
with decreased volumes in all brain regions, in particular the
gray matter (Geerlings et al., 2015). Similar findings have
been reported in the dementia-free Framingham Heart Study
participants: elevated cortisol was associated with decreased total
brain volume, in particular decreased occipital and frontal gray
matter volumes. In the same study, increased cortisol levels were
associated with some microstructural changes, specifically in the
corpus callosum and the posterior corona radiate (Echouffo-
Tcheugui et al., 2018).
In addition, high levels of cortisol have been linked to
hippocampal atrophy (Tatomir et al., 2014). This atrophy
can be the consequence of the exposure to increased
cortisol levels. Indeed, in Cushing’s disease, the observed
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FIGURE 3 | (A) In normal circumstances, the CRF released by the hypothalamus activates ACTH release by the pituitary gland, which stimulates the adrenal glands
to secrete cortisol. Cortisol inhibits its own secretion via a negative feedback loop. The hippocampus inhibits the hypothalamo-pituitary-adrenal axis. (B) When
cortisol is elevated, it can induce hippocampal atrophy, which “lifts the brake” on the hypothalamo-pituitary-adrenal axis. The resulting cortisol increase induces
further hippocampal atrophy, resulting in a vicious circle. CRF, corticotropin-releasing factor; ACTH, Adrenocorticotropic hormone.
hippocampal atrophy is reversed following treatment and
normalization of the cortisol levels (Starkman et al., 1999).
Yet, this atrophy can also be a cause of the elevated cortisol
levels. Indeed, the hippocampus exerts an inhibitory effect
on the HPA axis activity, and hence hippocampal atrophy
might disinhibit the HPA axis leading to increased cortisol
(Geerlings et al., 2015; Figure 3).
These effects on the hippocampal volume may be partly due to
changes in brain-derived neurotrophic factor (BDNF) expression
in the hippocampus (Suri and Vaidya, 2013). Similarly to their
effects on cognitive performance, MR activation seems to increase
whereas GR activation seems to decrease BDNF expression in the
hippocampus (Kino et al., 2010; Suri and Vaidya, 2013).
In a study by Cox et al. (2015) elevated salivary cortisol
levels at the start and at the end of a cognitive task
appointment have been associated with a poorer white matter
structure, i.e., greater white matter hyperintensity volume
and/or elevated general factor of tract mean diffusivity. These
findings suggest that aside from the “acute effects” of cortisol
on cognition, chronically elevated cortisol levels likely bring
about brain structural changes that may reflect long-term
cognitive deficits.
HPA-AXIS DYSREGULATION, CORTISOL
AND ALZHEIMER’S DISEASE
PATHOLOGY, DISEASE RISK AND
CLINICAL COURSE
Glucocorticoids have been reported to promote oxidative stress
and to increase amyloid β (Aβ) peptide toxicity in cultured
hippocampal neurons (Goodman et al., 1996). Besides, in
a mouse model of AD, elevated cortisol has been linked
to exacerbated Aβ peptide and tau pathology in the brain
(Green et al., 2006).
In primates, year-long high-dose exposure to glucocorticoids
was associated with decreased insulin-degrading enzyme levels,
a candidate protease for the clearance of Aβ in the brain. At the
same time, the Aβ1-42/Aβ1-40 ratio was increased indicating a
relative shift toward increased production of the more brain toxic
Aβ1-42 (Kulstad et al., 2005).
In a cross-sectional study examining the links between
cardiovascular risk factors and Aβ brain burden as determined
by Pittsburgh Compound B-positron emission tomography (PiB-
PET), an association has been found between plasma cortisol and
Aβ brain burden (Toledo et al., 2012).
Together, these findings suggest that increased cortisol may
induce and/or exacerbate cerebral AD pathology by increasing
Aβ brain burden, tau pathology as well as oxidative stress,
which can all contribute to neurodegeneration. Effects on Aβ
likely entail decreasing Aβ clearance as well as promoting
the cleavage of Aβ into the most toxic compound (Aβ1-42)
(Kulstad et al., 2005).
The aforementioned cerebral changes associated with elevated
cortisol likely translate into findings of associations between
increased cortisol levels and clinical features of AD, as shown
in several clinical studies that reported increased cortisol levels
in patients with clinical AD dementia (Dong and Csernansky,
2009; Popp et al., 2009; Ennis et al., 2017), and cortisol levels have
even been found to correlate with the severity of the cognitive
impairment (Pedersen et al., 2001; Zverova et al., 2013).
A prospective study by Ennis et al. (2017) S found that elevated
cortisol (as measured by the urinary free cortisol/creatinine ratio)
and elevated intra-subject cortisol variability (as measured by the
within-person urinary free cortisol/creatinine ratio variability)
were associated with a 1.31- and 1.38-times increase in AD
risk. Furthermore, in cognitively healthy older adults with Aβ
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positive PET imaging, high cortisol levels have been found to be
associated with a faster decline in global cognition, in episodic
memory, as well as in executive functioning, independently
of age, sex, APOE genotype, or anxiety symptoms (Pietrzak
et al., 2017). In a population based cohort study in 537 non-
demented older adults (65 years or more at baseline), we found
salivary cortisol day profiles to be not associated with faster
cognitive decline over an average 5.3 years. However, preliminary
analysis suggests that higher morning salivary cortisol measures
may be associated with slight decline in global cognition
(Albanese et al., 2018).
Higher plasma cortisol levels in patients with AD dementia
have been associated with a more rapid cognitive decline in some
studies (Pedersen et al., 2001; Huang et al., 2009). Similarly,
Csernansky et al. (2006) found that high plasma cortisol levels
were associated with faster cognitive decline in individuals with
very mild or mild AD dementia.
In a cohort study from the Alzheimer Disease Neuroimaging
Initiative (ADNI) investigating biomarkers able to predict
progression from mild cognitive impairment (MCI) to AD within
1–6 years, plasma cortisol was one of the six biomarkers found to
provide an accurate prediction (Lehallier et al., 2016).
Moreover, cortisol concentrations in the cerebrospinal fluid
(CSF) have been found to be higher in subjects with dementia
and MCI due to AD compared to control subjects (Popp
et al., 2009, 2015). In MCI due to AD, high CSF cortisol
was also predictive of a more rapid cognitive decline (Popp
et al., 2015). Hence, elevated cortisol appears to contribute to
exacerbate AD brain pathology, thereby contributing to the
disease progression both pathologically and clinically. Cortisol
levels appear to be increased at early stages of AD, and fasting
plasma and CSF cortisol levels may even be pre-clinical markers
(Notarianni, 2017).
These findings may be explained by increased Aβ
neurotoxicity related to higher cortisol levels as well as
neurodegeneration and functional impairment of the
hippocampus occurring early in the course of the disease
as both a consequence of exposure to high cortisol levels
and a cause of HPA axis disinhibition, hence a vicious circle
(Geerlings et al., 2015).
CORTISOL, COGNITION AND
MEDIATING FACTORS
Certain factors may further explain the links between cortisol,
cognitive impairment and dementia. Indeed, some of these
factors may bring about HPA axis alterations that could affect
cognition and the risk for dementia, in particular AD. These
factors may include life events (Ouanes et al., 2017a), personality
(Ouanes et al., 2017b; Tautvydaite et al., 2017; Terracciano et al.,
2017), sleep disorders (Haba-Rubio et al., 2017), depression
(Salvat-Pujol et al., 2017).
At the same time, some other factors such as metabolic
syndrome, insulin resistance and effects on inflammation may
mediate the effects of cortisol on cognition and brain structural
changes (Kim and Feldman, 2015; Martocchia et al., 2016).
Cortisol, Cognition, Trauma and Life
Events
Early trauma (of physical, sexual or emotional nature) has been
linked to long-term cognitive deficits in adulthood (consisting
in impaired spatial working memory and pattern recognition
memory) in a study by Majer et al. (2010); however, this finding
was not replicated in other studies (Saigh et al., 2006). Early
stress has also been shown to be associated with structural
and functional changes in brain regions involved in cognitive
functions, including the frontal cortex as well as the hippocampus
(Lupien et al., 2009).
Early trauma is also one of the most important established risk
factors for PTSD. PTSD has been shown to be associated with
an increased risk of dementia in both genders over an average of
8 years of follow-up (hazard ratio: 1.73[1.47, 2.02]) (Flatt et al.,
2017). Nevertheless, Burri et al. (2013) found that the long-term
cognitive deficits associated with PTSD were likely independent
of earlier childhood adversity.
Aside from early trauma and PTSD, stressful life events have
often been associated with HPA activation. Yet, some studies,
conversely, showed decreased cortisol following stressful life
events (Miller et al., 2007; Daskalakis et al., 2013). Results of
the studies exploring the relationship between life events and
cognition have been discrepant. On the one hand, several studies
highlighted associations between stressful events and poorer
subsequent cognitive performance, in particular in memory
and executive functions (Xavier et al., 2002; VonDras et al.,
2005; van Gelder et al., 2006; Lupien et al., 2007) above
and beyond the impact of depression (Comijs et al., 2011).
Importantly, stressful events have been also associated with an
elevated risk of late-life dementia (Johansson et al., 2010) and
late-life cerebral atrophy, and white matter lesions (Johansson
et al., 2012). On the other hand, other studies failed to find
any association between stressful life events and cognitive
performance in the elderly (Ward et al., 2007; Fountoulakis
et al., 2011; Sundstrom et al., 2014) and some even showed a
possible improvement in cognition following certain stressful
events (Deeg et al., 2005).
In a study exploring the mediation hypothesis between
cortisol, life events and cognition in 796 non-demented subjects
aged at least 65 we found elevated salivary cortisol levels to be
linked to poorer cognitive performance, but this association was
not related to life events (Ouanes et al., 2017a).
These discrepancies regarding the relationships between life
events and cortisol on the one hand, and life events and cognition
on the other hand, may be explained by different life events
displaying different effects on cortisol and thus on cognition
(Ouanes et al., 2017a).
Cortisol, Cognition and Personality
High neuroticism is the personality trait most consistently often
associated with high cortisol (Bridges and Jones, 1968; van
Eck et al., 1996; Miller et al., 1999, 2016; Portella et al., 2005;
Yoshino et al., 2005; Gerritsen et al., 2009; Nater et al., 2010;
Garcia-Banda et al., 2014). However, other studies found no
association (Adler et al., 1997; Schommer et al., 1999; Ferguson,
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2008), or even an opposite link (Ballenger et al., 1983; LeBlanc
and Ducharme, 2005).
Higher neuroticism has also been reported to be cross-
sectionally linked to lower cognitive performance above and
beyond the effects of depression (Jorm et al., 1993; Boyle et al.,
2010), especially to poorer episodic memory (Jorm et al., 1993;
Meier et al., 2002; Klaming et al., 2016). In addition, high
neuroticism scores have been found in association with elevated
risk of AD (Terracciano et al., 2014).
A few studies examined the relationship between the other
personality traits and cognitive performance and risk of
dementia. Lower pre-morbid conscientiousness, agreeableness,
openness and extraversion have been associated, although not
consistently, with lower cognitive performance and higher risk
for AD (Terracciano et al., 2014, 2017; Tautvydaite et al., 2017). In
a cohort of memory clinic patients and cognitively healthy elderly
volunteers we found lower extraversion and openness to correlate
with CSF markers of AD pathology: tau, ptau-181, tau/Aβ1–
42, and ptau-181/Aβ1–42 ratios, but not with the Aβ1–42 level
(Tautvydaite et al., 2017).
In a population-based cohort study examining the
interrelationships between cortisol, cognition and personality
traits, salivary cortisol did not seem to mediate the link between
personality traits and cognitive deficits (Ouanes et al., 2017b).
Besides methodological differences, these observed
discrepancies may be due to the impact of depression and/or
anxiety which has been controlled for in a few studies but
not in others, but also to the difficulties (in cross-sectional
studies, mainly) to disentangle pre-morbid personality
traits from the personality modifications accompanying the
cognitive decline.
Cortisol, Cognition and Sleep Disorders
Cognitive impairment has been associated with more time
spent in stage N1 (first step of non-rapid eye movement
sleep) and less in stage N3 (third step of non-rapid eye
movement sleep) and in REM sleep, lower sleep efficiency,
and more wake after sleep onset, as well as more severe sleep
disordered breathing (as evidenced by higher apnea/hypopnea
index or AHI, and higher oxygen desaturation index or ODI)
(Haba-Rubio et al., 2017).
In a study of the same research group, involving 456 elderly
non-demented subjects, obstructive sleep apnea (OSA) has been
found to be linked to cognitive impairment, but the relationship
did not appear to be mediated by diurnal cortisol levels (Haba-
Rubio et al., 2018).
In other studies, OSA has been associated with increased
nocturnal plasma cortisol levels (Chopra et al., 2017). Edwards
et al. (2014) found that higher night-time cortisol was
associated with worse cognitive performance, mainly affecting
memory, above and beyond the apnea severity in a sample of
patients with OSA.
Taken together, the results of these studies highlight
links between cognitive performance and sleep disorders
on the one hand, and between cortisol levels and
cognitive functioning on the other hand, but do not
provide evidence to support that cortisol may actually
mediate the relationship between sleep disorders and
cognitive impairment.
Cortisol, Cognition and Depression
Depression has been associated, on the one hand with HPA
axis hyperactivity and impaired negative feedback (Anacker
et al., 2011), and on the other hand with cognitive deficits
involving attention, episodic memory and executive functions
(Salvat-Pujol et al., 2017). Depression has also been tied
to late-life dementia, in particular with vascular and AD
dementia (Brunnstrom et al., 2013). This association is not
just a mere comorbidity, as late-life depression may also be
a risk factor for both AD and vascular dementia (Diniz
et al., 2013; Herbert and Lucassen, 2016). In the AGES-
Reykjavik population-based study (Geerlings et al., 2017), both
current major depressive disorder and high evening cortisol
levels were associated with an higher risk of incident AD
and non-AD dementia, but cortisol did not seem to be a
major factor explaining the relation between depression and
risk of dementia.
Some of the observed cognitive deficits in verbal and visual
memory and executive functions may remain present even after
the depressive symptoms fully remitted (Herrera-Guzman et al.,
2010; Rock et al., 2014; Salvat-Pujol et al., 2017). Likewise,
the HPA axis abnormalities associated with depression may
persist even after remission (Lok et al., 2012; Salvat-Pujol et al.,
2017), possibly constituting trait rather than state markers for
depression, even though this remains a matter of debate (Zverova
et al., 2013; Salvat-Pujol et al., 2017).
Remission status in depression did not moderate
the association between cognitive performance and the
Dexamethasone suppression test ratio or the cortisol
awakening response (CAR), defined by the increase in
cortisol secretion after awakening (Fries et al., 2009).
However, remission appeared to moderate the association
between cortisol slope defined by the difference between
maximal and minimal cortisol levels during the nyctemera,
and certain cognitive tasks assessing processing speed
and executive function (Salvat-Pujol et al., 2017). HPA
axis alteration in depression may inhibit neurogenesis,
partly through reducing BDNF which is involved in
hippocampal neurogenesis, thus possibly explaining one of
the mechanisms by which depression may be a risk factor for AD
(Herbert and Lucassen, 2016).
Delirium is common in AD, and it is associated with
more rapid clinical disease progression (Popp, 2013).
Depression symptoms and cognitive impairment have been
independently associated with higher risk of developing
delirium. In a yet-to be-published study by the same team,
increased cortisol levels have been observed in patients with
delirium suggesting HPA axis dysregulation to be involved
in the pathophysiology of delirium. In a cohort of elderly
patients undergoing elective cardiac surgery, pre-operative
geriatric depression scale scores were found to predict
post-operative delirium. However, pre-operative morning
plasma cortisol levels were not associated with post-operative
delirium in this study.
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Whether and how HPA axis dysregulation and increased
cortisol levels may contribute to the magnitude of
cognitive and non-cognitive symptoms in AD, needs
further investigation. In a study in patients with AD
dementia, plasma cortisol levels have been shown to
reflect the degree of cognitive deficits in AD dementia
rather than the severity of the comorbid depression
(Zverova et al., 2013).
Altogether, these data suggest that, mostly, cognitive deficits
linked to increased cortisol and HPA axis dysregulation
cannot be entirely explained by a co-occurring depressive
disorder. AD pathology may exacerbate HPA axis dysregulation
which may contribute to the manifestation of depressive
symptoms and to the severity of cognitive impairment
and increase the risk of other non-cognitive syndromes,
including delirium. Even though depression-associated HPA
axis dysregulation may predispose to and/or exacerbate the
course of AD (Herbert and Lucassen, 2016), studies suggest a
link between HPA axis dysregulation and AD itself above and
beyond depression.
Cortisol, Cognition and the Metabolic
Syndrome
Elevated cortisol levels have been tied to insulin resistance
and metabolic syndrome, which in turn, have been associated
with both AD and vascular dementia. (Kim and Feldman,
2015; Martocchia et al., 2016). Hence, elevated cortisol may
lead, through its metabolic syndrome-associated effects
on glucose, blood pressure and lipids, to an increased
cardiovascular risk (Lattanzi and Silvestrini, 2017). Indeed,
higher cortisol has been associated with a higher number
of carotid plaques (Hamer et al., 2010). The resulting
vascular lesions in the brain may directly induce cognitive
disturbances, but can also contribute to the neurodegeneration
observed in AD (Attems and Jellinger, 2014). Moreover, insulin
resistance itself may negatively influence the amyloid cascade
(Stefanelli et al., 2014).
At the same time, AD-associated hypercortisolemia, present
at very early stages, may also induce pre-diabetes. The
resulting increased insulin secretion can further exacerbate the
hypercortisolemia, thus possibly negatively affecting the course
of AD (Notarianni, 2017).
Cortisol, Cognition and Inflammation
While cortisol is generally known to exert broad anti-
inflammatory effects, high cortisol levels may activate
NACHT, LRR and PYD domains-containing protein 1
(NLRP-1) inflammasome in hippocampal neurons, thus
promoting neuroinflammation and thereby neuronal injury
(Zhang et al., 2017).
Moreover, certain cytokines, in particular IL-1-
Beta and IL-6, which are also known to be involved
in the pathophysiology of AD, can activate the HPA
axis (Besedovsky and del Rey, 2000). The resulting
increased cortisol can reinforce the toxic effects on the
hippocampus exerted by the pro-inflammatory cytokines
(Sudheimer et al., 2014), thus contributing to the
pathophysiology of AD.
CORTISOL AND POTENTIAL
PREVENTIVE AND THERAPEUTIC
INTERVENTIONS FOR ALZHEIMER’S
DISEASE:
Since increased cortisol has been associated with both AD
pathology and more rapid clinical disease progression, and
since most detrimental effects of cortisol are likely exerted
via GRs, therapeutic interventions targeting the GRs have
been investigated. Indeed, the GR antagonist mifepristone has
been shown to decrease both Aβ and tau load in the brain
as well as to improve the pathologically induced cognitive
impairments in a triple-transgenic (3xTg AD) mouse model
of AD (Baglietto-Vargas et al., 2013). In a similar way,
mifepristone has been shown to reduce the hippocampal Aβ
levels and rescue the cognitive deficits induced by early life
stress in APP/PS1 transgenic mice (Lesuis et al., 2018). As
these pathological processes start years or even decades before
the onset of the first symptoms, cortisol lowering or cortisol
effects modulating interventions in midlife may slow down
the development of amyloid pathology and neurodegeneration,
and prevent cognitive decline in later life (Lante et al., 2015;
Lesuis et al., 2018). Such interventions could prove useful,
in particular in subjects at risk for developing clinical AD
(Pietrzak et al., 2017) and prone to stress, and HPA-axis
dysregulation. Prevention trials with focus on cortisol or HPA-
axis in human subjects with normal cognition have not been
reported so far, however.
One randomized controlled trial in a small sample of patients
with mild to moderate AD dementia showed improvement of
cognitive performance in memory tasks, but the premature
termination did not allow any firm conclusions regarding efficacy
(Pomara et al., 2002). Other trials using mifepristone that were
initiated were terminated without being published, indicating
that these trials were not completed, or yielded negative results
(O’Banion, 2013).
Also, several non-pharmacological intervention in subjects
with MCI (Baker et al., 2010) or dementia (Woods et al., 2009;
Schaub et al., 2018) have shown cortisol lowering effects.
However, there has been some loss of interest in GR
antagonists because of their side effects due to GRs being
ubiquitous, especially as more selective molecules, namely GR
modulators have been developed (Canet et al., 2018).
Glucocorticoid Receptor modulators have been shown
to normalize basal glucocorticoid plasma levels, decrease
hippocampal Aβ peptide deposition, inhibit neuroinflammation,
and apoptotic processes, and improve cognitive performance in
a mouse model of AD (Pineau et al., 2016).
Another potential mechanism by which cortisol effects can
be reduced pharmacologically is the inhibition of cortisol
synthesis, one of the key enzymes being the 11β-hydroxysteroid
dehydrogenase type 1 (11β-HSD1). Currently, a phase II trial of
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an 11β-HSD1 inhibitor (UE2343) as a potential treatment for AD
is being conducted (Webster et al., 2017).
STRENGTHS AND LIMITATIONS
This narrative review provides a concise overview of the
different molecular, cellular, and clinical (including diagnostic,
prognostic, and therapeutic) aspects of the interrelationships
between cortisol, cognition, dementia, and AD. However, it does
not cover all possible facets of these complex relationships. We
focused on the most important and the most clinically relevant
aspects of the topic, rather going in depth into one particular
aspect of the topic.
CONCLUSION
There is a growing body of evidence that increased cortisol may
be deleterious for the late-life cognitive performance, and may
be associated with an increased risk for cognitive decline and
dementia, in particular dementia due to AD. In patients with AD,
the increased cortisol at preclinical and early clinical stages is
associated with a poorer prognosis and a more rapid cognitive
decline. Increased cortisol may represent a pathophysiological
mediator between stressful life events, personality, mood, and
sleep, and may increase both the risk of AD and the extent
of symptoms at clinical stages of the disease. Yet, the exact
underlying mediating factors are not fully understood. Direct
deleterious cortisol effects on the hippocampus and on the
prefrontal cortex are likely, but also cortisol links with metabolic
syndrome and neuroinflammation; and HPA axis disinhibition
due to neurodegeneration are other possible mechanisms that
may explain the association of cortisol with late-life cognitive
impairment and AD.
Further studies are needed to confirm the value of cortisol
levels as a possible preclinical marker associated with higher risk,
and/or as a prognostic parameter in subjects with clinical AD.
Future research may also bring in new HPA-based interventions
for the prevention and/or management of symptoms, and of the
clinical progression of AD.
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